{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T18:36:05Z","timestamp":1787337365486,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802512"],"award-info":[{"award-number":["81802512"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"DOI":"10.1007\/s13346-026-02199-2","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:03:00Z","timestamp":1787331780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Milk derived exosomes sensitize Gefitinib-resistant lung cancer cells to Pemetrexed via CAV1-mediated endocytosis"],"prefix":"10.1007","author":[{"given":"Tao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"3","key":"2199_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2199_CR2","doi-asserted-by":"publisher","first-page":"111450","DOI":"10.1016\/j.biopha.2021.111450","volume":"138","author":"S Xie","year":"2021","unstructured":"Xie S, Wu Z. The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges. Biomed Pharmacother. 2021;138:111450.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"2199_CR3","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","volume":"28","author":"MB Schabath","year":"2019","unstructured":"Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563\u201379.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"25","key":"2199_CR4","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"2199_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121\u20138.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2199_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357.","journal-title":"N Engl J Med"},{"issue":"2","key":"2199_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.21037\/tlcr.2016.04.07","volume":"5","author":"KR Jakobsen","year":"2016","unstructured":"Jakobsen KR, Demuth C. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res. 2016;5(2):172\u201382.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"2199_CR8","first-page":"67","volume":"4","author":"EL Stewart","year":"2015","unstructured":"Stewart EL, Tan SZ. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res. 2015;4(1):67\u201381.","journal-title":"Transl Lung Cancer Res"},{"issue":"7","key":"2199_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","volume":"11","author":"S Lu","year":"2023","unstructured":"Lu S, Wu L, Jian H, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023;11(7):624\u201336.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"2199_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","volume":"332","author":"W Fang","year":"2024","unstructured":"Fang W, Zhao Y, Luo Y, et al. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial. JAMA. 2024;332(7):561\u201370.","journal-title":"JAMA"},{"issue":"4","key":"2199_CR11","first-page":"1783","volume":"39","author":"J Zhou","year":"2018","unstructured":"Zhou J, Hu Q, Zhang X, et al. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition. Oncol Rep. 2018;39(4):1783\u201392.","journal-title":"Oncol Rep"},{"issue":"4","key":"2199_CR12","first-page":"1737","volume":"34","author":"G Spengler","year":"2014","unstructured":"Spengler G, Tak\u00e1cs D, Horv\u00e1th A, et al. Multidrug resistance reversing activity of newly developed phenothiazines on P-glycoprotein (ABCB1)-related resistance of mouse T-lymphoma cells. Anticancer Res. 2014;34(4):1737\u201341.","journal-title":"Anticancer Res"},{"issue":"1","key":"2199_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00432-022-04387-2","volume":"149","author":"D Shah","year":"2023","unstructured":"Shah D, Ajazuddin, Bhattacharya S. Role of natural P-gp inhibitor in the effective delivery for chemotherapeutic agents. J Cancer Res Clin Oncol. 2023;149(1):367\u201391.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2199_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/ijms251810008","volume":"25","author":"H Dickerson","year":"2024","unstructured":"Dickerson H, Diab A. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects. Int J Mol Sci. 2024;25:18.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2199_CR15","doi-asserted-by":"publisher","first-page":"10791","DOI":"10.1038\/s41598-021-89931-9","volume":"11","author":"W Yin","year":"2021","unstructured":"Yin W, Xiang D, Wang T, et al. The inhibition of ABCB1\/MDR1 or ABCG2\/BCRP enables doxorubicin to eliminate liver cancer stem cells. Sci Rep. 2021;11(1):10791.","journal-title":"Sci Rep"},{"issue":"3","key":"2199_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/ERC-18-0500","volume":"26","author":"SG Creemers","year":"2019","unstructured":"Creemers SG, van Koetsveld PM, De Herder WW, et al. MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer. Endocr Relat Cancer. 2019;26(3):367\u201378.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2199_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1124\/jpet.122.001234","volume":"384","author":"GM Traber","year":"2023","unstructured":"Traber GM, Yu AM. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies. J Pharmacol Exp Ther. 2023;384(1):133\u201354.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2199_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/med.21739","volume":"41","author":"H Zhang","year":"2021","unstructured":"Zhang H, Xu H. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med Res Rev. 2021;41(1):525\u201355.","journal-title":"Med Res Rev"},{"key":"2199_CR19","doi-asserted-by":"publisher","first-page":"216141","DOI":"10.1016\/j.canlet.2023.216141","volume":"561","author":"M Wallen","year":"2023","unstructured":"Wallen M, Aqil F. Milk\/colostrum exosomes: A nanoplatform advancing delivery of cancer therapeutics. Cancer Lett. 2023;561:216141.","journal-title":"Cancer Lett"},{"issue":"1","key":"2199_CR20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.7150\/ijbs.99954","volume":"21","author":"Z Xu","year":"2025","unstructured":"Xu Z, Wang L, Tu L, et al. Folic Acid-Modified Milk Exosomes Delivering c-Kit siRNA Overcome EGFR-TKIs Resistance in Lung Cancer by Suppressing mTOR Signaling and Stemness. Int J Biol Sci. 2025;21(1):382\u201399.","journal-title":"Int J Biol Sci"},{"key":"2199_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jconrel.2019.08.021","volume":"311\u2013312","author":"Z Zheng","year":"2019","unstructured":"Zheng Z, Li Z. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. J Control Release. 2019;311\u2013312:43\u20139.","journal-title":"J Control Release"},{"issue":"1","key":"2199_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/s12885-018-4418-2","volume":"18","author":"M Barok","year":"2018","unstructured":"Barok M, Puhka M. Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. BMC Cancer. 2018;18(1):504.","journal-title":"BMC Cancer"},{"issue":"7659","key":"2199_CR23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546(7659):498\u2013503.","journal-title":"Nature"},{"issue":"1","key":"2199_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s12010-018-2813-4","volume":"187","author":"SK Limoni","year":"2019","unstructured":"Limoni SK, Moghadam MF. Engineered Exosomes for Targeted Transfer of siRNA to HER2 Positive Breast Cancer Cells. Appl Biochem Biotechnol. 2019;187(1):352\u201364.","journal-title":"Appl Biochem Biotechnol"},{"key":"2199_CR25","first-page":"3","volume":"4","author":"LA Mulcahy","year":"2014","unstructured":"Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014;4:3.","journal-title":"J Extracell Vesicles"},{"issue":"5","key":"2199_CR26","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.3390\/ijms23052860","volume":"23","author":"A Gonz\u00e1lez-Sarr\u00edas","year":"2022","unstructured":"Gonz\u00e1lez-Sarr\u00edas A, Iglesias-Aguirre CE, Cort\u00e9s-Mart\u00edn A, et al. Milk-Derived Exosomes as Nanocarriers to Deliver Curcumin and Resveratrol in Breast Tissue and Enhance Their Anticancer Activity. Int J Mol Sci. 2022;23(5):2860.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2199_CR27","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1021\/acsabm.2c00015","volume":"5","author":"J Pullan","year":"2022","unstructured":"Pullan J, Dailey K, Bhallamudi S, et al. Modified Bovine Milk Exosomes for Doxorubicin Delivery to Triple-Negative Breast Cancer Cells. ACS Appl Bio Mater. 2022;5(5):2163\u201375.","journal-title":"ACS Appl Bio Mater"},{"issue":"19","key":"2199_CR28","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.3390\/cells11193065","volume":"11","author":"D Li","year":"2022","unstructured":"Li D, Gong L, Lin H, et al. Hyaluronic Acid-Coated Bovine Milk Exosomes for Achieving Tumor-Specific Intracellular Delivery of miRNA-204. Cells. 2022;11(19):3065.","journal-title":"Cells"},{"issue":"3","key":"2199_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s13577-025-01219-6","volume":"38","author":"H Li","year":"2025","unstructured":"Li H, Sun Y, Wang J, et al. Hyaluronic acid-modified milk exosomes carrying ZNF516 inhibit ABCC5 and contribute to pemetrexed sensitivity in lung adenocarcinoma. Hum Cell. 2025;38(3):92.","journal-title":"Hum Cell"},{"issue":"Pt 3","key":"2199_CR30","doi-asserted-by":"publisher","first-page":"137129","DOI":"10.1016\/j.ijbiomac.2024.137129","volume":"282","author":"A Zhang","year":"2024","unstructured":"Zhang A, Huang J, Liu Y, et al. Hyaluronic acid application strategies for plant bioactive component delivery: A review. Int J Biol Macromol. 2024;282(Pt 3):137129.","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"2199_CR31","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3390\/ijms22031105","volume":"22","author":"L Del Pozo-Acebo","year":"2021","unstructured":"Del Pozo-Acebo L, Hazas MLL, Tom\u00e9-Carneiro J, et al. Bovine Milk-Derived Exosomes as a Drug Delivery Vehicle for miRNA-Based Therapy. Int J Mol Sci. 2021;22(3):1105.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"2199_CR32","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.3390\/cancers13194926","volume":"13","author":"D Reita","year":"2021","unstructured":"Reita D, Pabst L, Pencreach E, et al. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. Cancers (Basel). 2021;13(19):4926.","journal-title":"Cancers (Basel)"},{"key":"2199_CR33","doi-asserted-by":"publisher","first-page":"102557","DOI":"10.1016\/j.ctrv.2023.102557","volume":"116","author":"Z Zalaquett","year":"2023","unstructured":"Zalaquett Z, Catherine Rita Hachem M, Kassis Y, et al. Acquired resistance mechanisms to Gefitinib: The constant battle. Cancer Treat Rev. 2023;116:102557.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"2199_CR34","doi-asserted-by":"publisher","first-page":"824","DOI":"10.7150\/thno.49600","volume":"11","author":"Q Zheng","year":"2021","unstructured":"Zheng Q, Dong H, Mo J, et al. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 2021;11(2):824\u201340.","journal-title":"Theranostics"},{"key":"2199_CR35","doi-asserted-by":"publisher","first-page":"114542","DOI":"10.1016\/j.ejmech.2022.114542","volume":"239","author":"K Engle","year":"2022","unstructured":"Engle K, Kumar G. Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update. Eur J Med Chem. 2022;239:114542.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"2199_CR36","doi-asserted-by":"publisher","first-page":"e13840","DOI":"10.1016\/j.heliyon.2023.e13840","volume":"9","author":"D Zhang","year":"2023","unstructured":"Zhang D, Jia T, Chen X, et al. Bufalin reverses ABCB1-mediated resistance to docetaxel in breast cancer. Heliyon. 2023;9(3):e13840.","journal-title":"Heliyon"},{"key":"2199_CR37","doi-asserted-by":"publisher","first-page":"873649","DOI":"10.3389\/fonc.2022.873649","volume":"12","author":"M Liu","year":"2022","unstructured":"Liu M, Xu C, Qin X, et al. DHW-221, a Dual PI3K\/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp\/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung Cancer. Front Oncol. 2022;12:873649.","journal-title":"Front Oncol"},{"issue":"1","key":"2199_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2217\/hep.15.41","volume":"3","author":"J Cox","year":"2016","unstructured":"Cox J, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol. 2016;3(1):57\u20139.","journal-title":"Hepat Oncol"},{"key":"2199_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","volume":"106","author":"L Amable","year":"2016","unstructured":"Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27\u201336.","journal-title":"Pharmacol Res"},{"key":"2199_CR40","doi-asserted-by":"publisher","first-page":"107447","DOI":"10.1016\/j.pharmthera.2019.107447","volume":"206","author":"S Vodenkova","year":"2020","unstructured":"Vodenkova S, Buchler T. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther. 2020;206:107447.","journal-title":"Pharmacol Ther"},{"key":"2199_CR41","doi-asserted-by":"publisher","first-page":"101100","DOI":"10.1016\/j.drup.2024.101100","volume":"76","author":"N Ji","year":"2024","unstructured":"Ji N, Li H, Zhang Y, et al. Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration. Drug Resist Updat. 2024;76:101100.","journal-title":"Drug Resist Updat"},{"issue":"5","key":"2199_CR42","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2174\/0113892010284774240328144105","volume":"26","author":"Z Abbasfard","year":"2025","unstructured":"Abbasfard Z, Behzad-Behbahani A, Rastegari B. SiRNA-Mediated Knockdown of ABCB1 Enhances the Efficacy of Doxorubicin and Vinorelbine in Breast Cancer Cells. Curr Pharm Biotechnol. 2025;26(5):716\u201327.","journal-title":"Curr Pharm Biotechnol"},{"issue":"2","key":"2199_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.31083\/ph.2021.0128","volume":"76","author":"XM Xi","year":"2021","unstructured":"Xi XM, Xia SJ. Drug loading techniques for exosome-based drug delivery systems. Pharmazie. 2021;76(2):61\u20137.","journal-title":"Pharmazie"},{"key":"2199_CR44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jconrel.2017.09.019","volume":"266","author":"H Costa Verdera","year":"2017","unstructured":"Costa Verdera H, Gitz-Francois JJ. Cellular uptake of extracellular vesicles is mediated by clathrin-independent endocytosis and macropinocytosis. J Control Release. 2017;266:100\u20138.","journal-title":"J Control Release"},{"issue":"1","key":"2199_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12943-021-01307-9","volume":"20","author":"S Wu","year":"2021","unstructured":"Wu S, Luo M, To KKW, et al. Intercellular transfer of exosomal wild type EGFR triggers Gefitinib resistance in non-small cell lung cancer. Mol Cancer. 2021;20(1):17.","journal-title":"Mol Cancer"},{"key":"2199_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev-cellbio-100617-062737","volume":"34","author":"RG Parton","year":"2018","unstructured":"Parton RG, Caveolae. Structure, Function, and Relationship to Disease. Annu Rev Cell Dev Biol. 2018;34:111\u201336.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"2","key":"2199_CR47","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10555-020-09890-x","volume":"39","author":"L Sim\u00f3n","year":"2020","unstructured":"Sim\u00f3n L, Campos A. Caveolin-1 function at the plasma membrane and in intracellular compartments in cancer. Cancer Metastasis Rev. 2020;39(2):435\u201353.","journal-title":"Cancer Metastasis Rev"},{"issue":"25","key":"2199_CR48","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1038\/sj.onc.1206625","volume":"22","author":"E Burgermeister","year":"2003","unstructured":"Burgermeister E, Tencer L. Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene. 2003;22(25):3888\u2013900.","journal-title":"Oncogene"},{"issue":"1","key":"2199_CR49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000235927","volume":"47","author":"Q Hu","year":"2010","unstructured":"Hu Q, Zhang XJ. PPARgamma1-induced caveolin-1 enhances cholesterol efflux and attenuates atherosclerosis in apolipoprotein E-deficient mice. J Vasc Res. 2010;47(1):69\u201379.","journal-title":"J Vasc Res"},{"issue":"42","key":"2199_CR50","doi-asserted-by":"publisher","first-page":"e2303774120","DOI":"10.1073\/pnas.2303774120","volume":"120","author":"JA Caruso","year":"2023","unstructured":"Caruso JA, Wang X, Murrow LM, et al. Loss of PPAR\u03b3 activity characterizes early protumorigenic stromal reprogramming and dictates the therapeutic window of opportunity. Proc Natl Acad Sci U S A. 2023;120(42):e2303774120.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02199-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02199-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02199-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T18:02:41Z","timestamp":1787335361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02199-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":50,"alternative-id":["2199"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02199-2","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal experiments were approved by the Animal Ethical Committee of West China Hospital, Sichuan University.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors agree to publish.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}